Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Nov 25

PMID 38001961

Authors

Lars Schroder

Christian M Domroese

Alexander B A Rupp

Kathrin M E Gihr

Christoph Niederau

Michael R Mallmann

Stefan Holdenrieder

Affiliations

Soon will be listed here.

Abstract

Background: Nowadays there still is no sufficient screening tool for ovarian and uterine cancer.

Objective: The current study aimed to investigate whether cancer antigen 125 (CA-125), tissue polypeptide antigen (TPA) or the combination of both markers are able to act as screening tools for ovarian or uterine cancer.

Methods: A total of 275 blood samples from different cohorts (ovarian cancer, uterine cancer, benign control group) were prospectively drawn and analyzed.

Results: Established biomarkers TPA and CA-125 showed elevated serum concentrations in patients with malignant tumors as compared to healthy women and women with benign diseases. In ROC curve analyses, both biomarkers were well able to discriminate between malignant and healthy, benign or overall non-malignant cases in the whole sample, with AUCs of 0.842 and above. While TPA was the best diagnostic marker in patients with uterine cancer, CA 125 was the best in patients with ovarian cancer.

Conclusions: TPA and CA-125 both showed promising results for the detection of gynecologic malignancies. The combination of CA-125 and TPA did not improve sensitivity in comparison to single markers.

Citing Articles

Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.

Schroder L, Rupp A, Gihr K, Kobilay M, Domroese C, Mallmann M Cancers (Basel). 2023; 15(20).

PMID: 37894448 PMC: 10605106. DOI: 10.3390/cancers15205081.

References

Jacobs I, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi J . Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2015; 387(10022):945-956. PMC: 4779792. DOI: 10.1016/S0140-6736(15)01224-6. View

Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K . Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(11):1902-12. DOI: 10.1158/1055-9965.EPI-12-0646. View

Lv X, Zhu Y, Liu J, Ai H . The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2017; 20(24):5113-5116. View

Reid B, Permuth J, Sellers T . Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9-32. PMC: 5365187. DOI: 10.20892/j.issn.2095-3941.2016.0084. View

Dorigo O, Berek J . Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila). 2011; 4(9):1356-9. DOI: 10.1158/1940-6207.CAPR-11-0378. View

Bian J, Sun X, Li B, Ming L . Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer. Technol Cancer Res Treat. 2016; 16(4):435-439. PMC: 5616069. DOI: 10.1177/1533034616666644. View

Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M . Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol. 2006; 103(3):924-31. DOI: 10.1016/j.ygyno.2006.05.047. View

Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S, Colas E . Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020; 9(6). PMC: 7356541. DOI: 10.3390/jcm9061900. View

Nithin K, Sridhar M, Srilatha K, Habebullah S . CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding. Afr Health Sci. 2019; 18(4):972-978. PMC: 6354887. DOI: 10.4314/ahs.v18i4.17. View

10.

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

11.

Morgan Jr R, Armstrong D, Alvarez R, Bakkum-Gamez J, Behbakht K, Chen L . Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(9):1134-63. DOI: 10.6004/jnccn.2016.0122. View

12.

Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano A . A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). Int J Oncol. 2021; 59(1). PMC: 8208622. DOI: 10.3892/ijo.2021.5233. View

13.

Pittaway D, Fayez J . Serum CA-125 antigen levels increase during menses. Am J Obstet Gynecol. 1987; 156(1):75-6. DOI: 10.1016/0002-9378(87)90207-9. View

14.

Reijnen C, Visser N, Kasius J, Boll D, Geomini P, Ngo H . Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019; 30(5):e70. PMC: 6658593. DOI: 10.3802/jgo.2019.30.e70. View

15.

Bottoni P, Scatena R . The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867:229-44. DOI: 10.1007/978-94-017-7215-0_14. View

16.

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

17.

Soletormos G, Duffy M, Othman Abu Hassan S, Verheijen R, Tholander B, Bast Jr R . Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer. 2015; 26(1):43-51. PMC: 4679342. DOI: 10.1097/IGC.0000000000000586. View

18.

Henley S, Miller J, Dowling N, Benard V, Richardson L . Uterine Cancer Incidence and Mortality - United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(48):1333-1338. PMC: 6329484. DOI: 10.15585/mmwr.mm6748a1. View

19.

Duk J, Bouma J, Burger G, Nap M, de Bruijn H . CA 125 in serum and tumor from patients with uterine sarcoma. Int J Gynecol Cancer. 1994; 4(3):156-160. DOI: 10.1046/j.1525-1438.1994.04030156.x. View

20.

Berardi R, Morgese F, Rinaldi S, Torniai M, Mentrasti G, Scortichini L . Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management. Cancer Manag Res. 2020; 12:9363-9374. PMC: 7533227. DOI: 10.2147/CMAR.S220976. View